Quoted from http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/stronger-warning-on-iclusig-blood-clot-risk/20066975.article
Stronger warning on Iclusig blood clot riskThe Pharmaceutical Journal, 30 OCT 2014
Warnings about the risks of developing a blood clot or blocked artery with Iclusig (ponatinib), a leukaemia treatment, are to be made more robust, following the results of a European Medicines Agency (EMA) review.
The EMA said that any risks would be likely to be linked to dosage but insufficient data meant that it did not have enough information to recommend that the existing starting dose of 45mg a day should change. The agency announced that it is launching a study into the safety and benefits of Iclusig, with a focus on dosage, to help clarify whether lowering the dose would also reduce the associated risks.
[Article continues at original source]